Skip to main content
. 2019 Sep 23;63(10):e01006-19. doi: 10.1128/AAC.01006-19

FIG 4.

FIG 4

The pyrimidinetrione amide lacks in vivo efficacy. (A) PK profile of compound 10 after twice-daily administration at 30 mg/kg. (B) M. tuberculosis bacterial burdens in infected mice after 2 and 4 weeks of once-daily or twice-daily treatment at 30 and 15 mg/kg, respectively. Treatment was initiated at 2 weeks after aerosol infection of the mice. The error bars indicate SD. Q, once daily; B, twice daily.